A month after efficacy findings from a pivotal Phase III study of VEN 307 (diltiazem hydrochloride cream) in anal fissures drove share prices higher, Ventrus Biosciences Inc. faced the market's wrath after its randomized, double-blind, placebo-controlled Phase III trial of VEN 309 (iferanserin ointment) failed in hemorrhoidal disease.